892 Shares in Humana Inc. $HUM Bought by Venturi Wealth Management LLC

Venturi Wealth Management LLC purchased a new stake in Humana Inc. (NYSE:HUM) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 892 shares of the insurance provider’s stock, valued at approximately $218,000.

Several other hedge funds have also recently added to or reduced their stakes in HUM. Revolve Wealth Partners LLC acquired a new stake in shares of Humana in the fourth quarter worth approximately $202,000. GAMMA Investing LLC raised its stake in shares of Humana by 54.9% during the first quarter. GAMMA Investing LLC now owns 2,952 shares of the insurance provider’s stock valued at $781,000 after purchasing an additional 1,046 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Humana by 8.2% during the first quarter. Assenagon Asset Management S.A. now owns 5,378 shares of the insurance provider’s stock valued at $1,423,000 after purchasing an additional 409 shares during the period. CX Institutional purchased a new stake in shares of Humana during the first quarter valued at approximately $213,000. Finally, Fifth Third Bancorp increased its stake in shares of Humana by 14.4% in the first quarter. Fifth Third Bancorp now owns 8,228 shares of the insurance provider’s stock worth $2,177,000 after buying an additional 1,034 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM opened at $280.24 on Friday. The firm has a market capitalization of $33.70 billion, a PE ratio of 21.51, a P/E/G ratio of 1.65 and a beta of 0.42. The stock has a 50 day simple moving average of $279.45 and a 200 day simple moving average of $258.13. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $315.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The company had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. During the same quarter in the prior year, the company earned $6.96 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 annualized dividend and a yield of 1.3%. Humana’s dividend payout ratio (DPR) is 27.17%.

Analysts Set New Price Targets

A number of equities analysts have commented on HUM shares. Barclays decreased their price objective on shares of Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a report on Friday, October 3rd. Wells Fargo & Company boosted their price target on shares of Humana from $344.00 to $347.00 and gave the company an “overweight” rating in a report on Tuesday. Sanford C. Bernstein boosted their price target on shares of Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Piper Sandler cut their price objective on Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a report on Thursday, July 31st. Finally, Evercore ISI initiated coverage on Humana in a research note on Monday, September 22nd. They set an “in-line” rating and a $295.00 target price on the stock. Seven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $298.00.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.